

Regular Meeting of the

## Santa Clara County Health Authority Pharmacy & Therapeutics Committee

Thursday, December 17, 2020, 6:00 PM – 8:00 PM

Santa Clara Family Health Plan

6201 San Ignacio Ave, San Jose, CA 95119

# Minutes (Open) - Approved

---

### Members Present

Jimmy Lin, MD, Chair  
Ali Alkoraishi, MD  
Amara Balakrishnan, MD  
Hao Bui, BS, RPh  
Xuan Cung, PharmD  
Dang Huynh, PharmD, Director of Pharmacy and UM  
Laurie Nakahira, DO, Chief Medical Officer  
Peter Nguyen, DO

### Members Absent

Dolly Goel, MD  
Jesse Parashar-Rokicki, MD  
Narinder Singh, PharmD

### Staff Present

Duyen Nguyen, PharmD, Clinical Pharmacist  
Tami Otomo, PharmD, Clinical Pharmacist  
Kristine Zhang, PharmD, Clinical Pharmacist  
Jayne Giangreco, Manager, Administrative  
Services  
Nancy Aguirre, Administrative Assistant

### Others Present

Amy McCarty, PharmD  
Shelly Tausing, Pharmacy Student

## 1. Roll Call

Jimmy Lin, MD, Chair, called the meeting to order at 6:09 pm. Roll call was taken and a quorum was established.

## 2. Public Comment

There were no public comments.

## 3. Meeting Minutes

The 3Q2020 P&T Committee Open meeting minutes were reviewed.

**It was moved, seconded and the open minutes of the September 17, 2020 P&T meeting were unanimously approved.**

**Motion:** Dr. Lin

**Second:** Dr. Cung

**Ayes:** Dr. Alkoraishi, Dr. Balakrishnan, Ms. Bui, Dr. Huynh, Dr. Nakahira,

**Absent:** Dr. Goel, Dr. Nguyen, Dr. Parashar-Rokicki, Dr. Singh

#### 4. Standing Agenda Items

##### a. Chief Medical Officer Health Plan Updates

Laurie Nakahira D.O., Chief Medical Officer (CMO), shared Santa Clara Family Health Plan (SCFHP) and Anthem Blue Cross collaborated to host 10 flu shot clinics. The clinics were free to everyone, including those without health insurance. Further information is available on the SCFHP website.

The current Plan membership is at a total of 250,000 members. Numbers have been increasing due to not disenrolling some of the Medi-Cal (MC) and Cal MediConnect (CMC) members.

Dr. Nakahira announced the DHCS and DMHC audits will be taking place in March, 2021. Touching base on the previously mentioned CalAIM, Dr. Nakahira was pleased to announce CalAIM will be brought back after being put on hold due to COVID-19 and the budget. The new start date for CalAIM with enhanced Case Management and In Lieu of Services is January 2022.

Dr. Nakahira briefly mentioned MediCal's Pharmacy Carve Out was due to start on 01/01/2021, but has now been postponed to 04/01/2021. This postponement will allow the Plan to better prepare for the transition.

Dr. Nakahira reported, as of yesterday, SCFHP has approximately 3,400 members that are positive with COVID-19 and about 1,300 of those members have been hospitalized. Ninety-five (95) members have passed away from COVID-19; 50 of them have been at a Skilled Nursing Facility (SNF) and 45 have been outside of a hospital. This represents about 17% of deaths within the county.

Dr. Nakahira updated the committee with the latest news regarding the recently approved Pfizer vaccine. The county started to vaccinate, beginning with Phase 1A. Phase 1A includes frontline workers and long term care residents and workers. The State estimates California will receive approximately 1.8 million vaccines by the end of this year (2021). This reflect approximately 4.5% of the state's population. There are about 1.7 million healthcare workers in California and about 640,000 nursing home residents and workers.

Dr. Nakahira added SCFHP is working with the Public Health Department as well as the State to develop ways to message the population and the community about risks involved in taking/not taking the vaccine.

##### b. Medi-Cal Rx Update

Dang Huynh, PharmD, Director, Pharmacy & Therapeutics, presented the Medi-Cal Rx update. As mentioned by Dr. Nakahira, MediCal's Pharmacy Carve Out has been delayed to start on 04/01/2021. DHCS will communicate the delay with all beneficiaries, including our Managed Care members. There are minor formulary changes, in terms of SCFHP's authorization process, that will be discussed later in this meeting.

##### c. Policy Review

###### i. PH10 CMC Part D Transition

Dr. Huynh reviewed the Pharmacy Policy PH10 CMC Part D Transition (2021), specific to CMC. CMS requires annual submission of this policy.

**It was moved, seconded and the Pharmacy Policy PH10 CMC Part D Transition was unanimously approved.**

**Motion:** Dr. Lin

**Second:** Dr. Balakrishnan

**Ayes:** Dr. Alkoraishi, Ms. Bui, Dr. Cung, Dr. Huynh, Dr. Nakahira

**Absent:** Dr. Nguyen, Dr. Parashar-Rokicki, Dr. Singh

## 5. Plan/Global Medi-Cal Drug Use Review

### a. Drug Use Evaluation Update

Tami Otomo, PharmD, Clinical Pharmacist, shared the results from SCFHP's quarterly retrospective Drug Use Evaluation (DUE). The clinical topics and data are chosen and provided by MedImpact. The first program reviewed was Asthma DUE. The success rate for Medi-Cal was 61% and 57% for CMC. The second program reviewed was the Polypharmacy DUE. This program was only made available for CMC, not Medi-Cal.

Dr. Otomo noted program letters for both Asthma DUE and Polypharmacy DUE were mailed on 11/03/2020. Follow up results will be shared next year. No questions were asked.

### b. 2019 4<sup>TH</sup> Quarter Emergency Supply Report

Duyen Nguyen, PharmD, Clinical Pharmacist, reviewed the 2019 4<sup>th</sup> Quarter Emergency Supply Report. Dr. Nguyen noted the key diagnosis used was urinary tract infection (UTI) due to clinical determination that such a diagnosis will require a prescription. No readmissions for the same diagnosis were found for the sampled members from the previous quarter, 2019Q3.

Dr. Nguyen added SCFHP will continue the quarterly assessments of emergency prescription access with medical and pharmacy data.

### c. Grievance & Appeals Pharmacy Report: 2020 1<sup>st</sup> – 3<sup>rd</sup> Quarter Reports

Dr. Huynh presented the G&A Pharmacy Report: 2020 1<sup>st</sup> – 3<sup>rd</sup> Quarter Reports in Charlene Luong's absence. While presenting this information at the previous P&T Committee meeting, two inconsistencies in reporting numbers were identified.

Dr. Huynh reviewed the updated data. For Q1 Medi-Cal February Overturns, the total number of overturns was changed from 18 to 19. For Q2 CMC, there was a rationale that was missing, which was non-covered benefit.

Dr. Huynh reviewed the Q3 2020 Medi-Cal Appeals Volume, Appeals by Decision, and Appeals by Rationale. Dr. Huynh also reviewed the Q3 2020 CMC Appeals Volume, Appeals by Decision, and Appeals by Rationale. No questions were asked.

***Adjourned to Closed Session at 6:36 p.m.***

***Pursuant to Welfare and Institutions Code Section 14087.36 (w)***

## 6. Closed Meeting Minutes

The 3Q2020 P&T Committee Closed meeting minutes were reviewed.

**It was moved, seconded and the closed minutes of the September 17, 2020 P&T meeting were unanimously approved.**

## 7. Metrics and Financial Updates

### a. Membership Report

Dr. Nakahira presented the membership report during the CMO Health Plan Updates.

### b. Pharmacy Dashboard

Dr. Otomo reviewed the Pharmacy Dashboard for August 2020 through November 2020.

### c. Pharmacy Member Portal Stats

Dr. Huynh presented the Pharmacy Member Portal Stats.

**d. Drug Utilization & Spend**

Dr. McCarty presented the Drug Utilization and Spend for Q3 2020.

**8. Discussion and Recommendations for Changes to SCFHP's Cal MediConnect Formulary & Coverage Determination Criteria**

**a. Pharmacy Benefit Manager 3Q2020 P&T Minutes**

Dr. McCarty reviewed the Pharmacy Benefit Manager 3Q2020 P&T Minutes.

**b. Pharmacy Benefit Manager 4Q2020 P&T Part D Actions**

Dr. McCarty reviewed the Pharmacy Benefit Manager 4Q2020 P&T Part D Actions.

**It was moved, seconded and the Pharmacy Benefit Manager 3Q2020 and 4Q2020 Part D Actions were unanimously approved.**

**c. 2021 Medical Benefit Drug Prior Authorization Grid**

Dr. Otomo reviewed the 2021 Medical Benefit Drug Prior Authorization Grid.

**It was moved, seconded and the 2021 Medical Benefit Drug Prior Authorization Grid was unanimously approved.**

**9. Discussion and Recommendations for Changes to SCFHP's Medi-Cal and Prior Authorization Criteria**

**a. Old Business/Follow-Up**

**i. Cefdinir Point-of-sale Message Update**

Dr. Nguyen provided a follow-up from the last meeting regarding the Q3 Emergency Supply Report.

**b. Formulary Modifications**

Dr. Otomo presented the changes made to the Medi-Cal formulary since the September 2020 P&T Committee meeting.

**It was moved, seconded and the Medi-Cal Formulary Additions and Modifications were unanimously approved.**

**c. Fee-for-Service Contract Drug List Comparability**

Dr. McCarty reviewed the Fee-for-Service Contract Drug List (CDL) Comparability for Medi-Cal.

**It was moved, seconded and the Fee-for-Service CDL Comparability proposed actions were unanimously approved.**

**d. 2021 Medical Benefit Drug Prior Authorization Grid**

Dr. Otomo presented the 2021 Medical Benefit Drug Prior Authorization Grid.

**It was moved, seconded and the Medi-Cal 2021 Medical Benefit Drug Prior Authorization Grid was unanimously approved.**

**e. Prior Authorization Criteria**

Dr. Nguyen reviewed the Prior Authorization Criteria.

**i. New or Revised Criteria**

1. Protopic ointment – *revised*
2. Non-Formulary – *revised*

**ii. Annual Review**

1. Norditropin Flexpro – *no changes*
2. Zarxio – *no changes*

**It was moved, seconded and the Prior Authorization Criteria was unanimously approved.**

**Peter Nguyen joined the meeting at approximately 7:21 p.m.**

**10. New Drugs and Class Reviews**

Kristine Zhang, PharmD, PGY-2 Administration Pharmacy Resident, presented the new drugs and class reviews.

**a. Tardive Dyskinesia Review.**

**b. COVID-19 Vaccines.**

**c. Asthma Review**

**d. Hereditary Angioedema (HAE) – Orladeyo**

Presented by Dr. McCarty.

**e. New & Expanded Indications – Epidiolex, Spravato, Tremfya, and Simponi Aria**

Presented by Dr. McCarty.

**It was moved, seconded and the New & Expanded Indications were unanimously approved.**

**f. Informational Only**

- i. Anemia Chronic Kidney Disease – Roxadustat
- ii. Systemic Lupus Erythematosus – Anifrolumab and Voclosporin
- iii. Acne – Winlevi
- iv. Duchenne Muscular Dystrophy – Viltepso
- v. Pain from Osteoarthritis – Tanezumab
- vi. Schizophrenia – Olanzapine/Samidorphan
- vii. Fatty Acid Metabolism – Dojolvi
- viii. Attention Deficit Hyperactivity Disorder – Viloxazine
- ix. Overactive Bladder – Vibegron
- x. Heart Failure – Vericiguat
- xi. Chemo-induced Neutropenia – Rolontis
- xii. Hyperlipidemia – Inclisiran
- xiii. Ophthalmic NSAIDs

**Reconvene in Open Session at 7:41 p.m.**

**11. Discussion Items**

**a. New and Generic Pipeline**

Ms. McCarty reviewed the new and generic pipeline. Roxadustat, an oral for anemia of CKD, released in 4Q2020, will compete with the injectable drugs. Dr. McCarty noted teplizumab, a development designed to delay Type 1 Diabetes, is to be released in 3Q2021.

Dr. McCarty noted a generic product made available in 4Q2020, Vascepa.

**Dr. Huynh noted a member from the public, Shelly Tausing, a Pharmacy student, joined the Open Session.**

**Dr. Balakrishnan announced her retirement from the Pharmacy & Therapeutics Committee.**

**12. Adjournment**

The meeting adjourned at 7:58 p.m. The next P&T Committee meeting will be on Thursday, March 18, 2021.

---

Jimmy Lin, MD, Chair

---

Date